Navigation Links
Cell Therapeutics Announces Institutional Investor Purchased Additional $15 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
Date:7/30/2012

rations, competitive factors, technological developments, costs of developing, producing and selling its drug candidates. Further risks and uncertainties include CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to further reduce its operating expenses, that CTI will continue to need to raise capital to fund its operating expenses and may not be able to raise sufficient amounts to fund its continued operation as well as other risks listed or described from time to time in CTI's most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K. Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell
T: 206.272.4345
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
(Date:7/24/2014)... July 24, 2014 Omnicell, Inc. (NASDAQ: ... medication and supply management solutions and analytics software ... July 31, to discuss the Company,s Second Quarter ... Quarter 2014 earnings conference call and webcastWhen: ... Randall Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based ... results for the second quarter ended June 30, 2014. ... of $6.5 million in the second quarter of 2014, an ... , Total revenues of $13.3 million for the six months ... same period in 2013 , Total revenues generated from ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... MicroCHIPS, Inc., a developer of innovative drug delivery ... Office and Trademark Office has granted U.S. Patent No. ... This patent in conjunction with U.S. Patent No. 7,070,590 ... reservoir-based medical devices used for implantable drug delivery systems. ...
... Promidian, a management consulting firm focused on ... survey findings about the increasing interest in the ... that is rapidly gaining nationwide attention for its ... care—while reducing costs. The Promidian ...
Cached Medicine Technology:MicroCHIPS Announces 35th U.S. Patent for Microreservoir-Based Drug Delivery Systems 2Promidian Survey Finds Growing Support for Patient-Centered Medical Home 2
(Date:7/27/2014)... 2014 This is a professional ... Dutasteride (CAS 164656-23-9) industry. The report firstly reviews ... its classification, application and manufacturing technology. The report ... Dutasteride (CAS 164656-23-9) listing their product specification, capacity, ... report further analyzes quantitatively 2009-2014 global and China’s ...
(Date:7/27/2014)... July 27, 2014 The report ... in Aviation - Market Analysis (Commercial Aviation And ... Pneumatic, Hydraulic, Mechanical) - Forecasts 2014 - 2019." ... are expected to shape the market during the ... and technology trends that are currently prevailing in ...
(Date:7/27/2014)... News) -- Couples aren,t more likely to get divorced ... new research finds. The study only looks at ... play a direct role in affecting whether couples stay ... speak against fears that women,s growing educational advantage over ... Schwartz, lead author of the study, said in an ...
(Date:7/27/2014)... July 27, 2014 Alta Resources ... outsourcing (BPO) for Fortune 500 brands, announced today that ... its locations in Wisconsin, California, Florida and the Philippines. ... several health-insurance clients, which have seasonal ramp-ups that require ... (AEP), November 2014 through February 2015. As more consumers ...
(Date:7/27/2014)... 27, 2014 The Institute of Safe ... adverse events such as Xarelto bleeding side-effects reported after ... out numbered the complaints filed for its competitor Pradaxa, ... for Xarelto increased to nearly 1 million prescriptions per ... early 2012, the ISMP noted in its latest issue ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 2Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 3Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 4Health News:Wives' Higher Education May Not Affect Divorce Rate 2Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 2Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 3Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 4Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 5
... chronic hepatitis C are at risk of suffering from ... weeks from commencement of treatment, says the researchers in a ... Science (IOVS)in the January 2007 issue. ,Researchers from ... in diameter of blood vessels and the velocity of ...
... that suggests a link between a particular gene named ... journal, Neurobiology of Aging, published the results of the ... implicated in causing Alzheimer’s disease. ,This research now ... raises the possibility that occurrence of herpes infection earlier ...
... have to prescribe medicines by their generic names instead of ... ,"We have issued a letter in this regard to all ... and dispensaries," Singh told IANS. ,The doctors ... not the brand names. Failure to do so would call ...
... Leading pharmaceutical company Lupin Ltd has received tentative approval ... its generic drug Sertraline Hydrochloride for// treatment of major ... will be the AB-rated generic equivalent of Pfizer's Zoloft ... ,"The company intends to launch the generic (drug) ...
... were thought to be far cleaner and healthier as compared ... not true- inner cities are a haven// for unhealthy habits ... smoking and disease rates and dietary habits to understand the ... that towns such as Merthyr Tydfil in Wales happened to ...
... be used for 15 minutes before sleeping to treat insomnia ... based company Helicor, is under clinical trial on 100 patients ... heartbeat by regulated deep breathing, said the online edition of ... several other conditions including anxiety and panic attacks, is said ...
Cached Medicine News:Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 2Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 3Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 4
This product is for the lower body and uses a Convective Warming System which is both soft and comfortable. Constructed of 2-ply material consisting of polyethylene film inner layer and non-woven out...
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
CritiCool™ offers precise cooling to the programmed target temperature by applying temperature control algorithm....
Medicine Products: